文献速递糖尿病

新诊断1型糖尿病青少年患者报告结局与残余β细胞功能及代谢参数的关系

Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes.
PubMed 文献 · Diabetologia · 2026-07-17

该研究基于CLOuD(N=97)和USTEKID(N=72)两项临床试验,分析10-18岁新诊断1型糖尿病患者的PedsQL和HFS评分与C肽、HbA1c及CGM指标的关系。结果显示PROMs评分在诊断后48个月内个体内变化不大,与血糖管理指标呈适度但显著的关联,而与残余β细胞功能的关联较弱且未达统计学显著性。

要点

  • PedsQL和HFS评分在诊断后48个月内个体内变化不大,基线评分可高度预测12-48个月评分。
  • 儿童PedsQL评分高于家长报告,而家长HFS评分高于儿童,提示家长恐惧低血糖更明显。
  • PROMs与HbA1c和CGM time in range呈适度显著关联,但与C肽的关联较弱且未达显著。

核心结论

  • PedsQL和HFS评分在新诊断1型糖尿病后48个月内变化不大。
  • 这些评分与血糖管理指标(HbA1c和CGM time in range)呈适度但统计学显著的关联。
  • 与残余β细胞功能(C肽)的关系较弱且未达统计学显著性。
  • 当前PROMs仅捕获β细胞保护相关临床获益的有限方面。

研究设计与样本

  • 研究基于两项临床试验CLOuD(N=97,混合闭环vs每日多次注射)和USTEKID(N=72,ustekinumab免疫治疗vs安慰剂)。
  • 纳入10-18岁新诊断1型糖尿病参与者及其家长,重复记录PedsQL和HFS评分。
  • 将评分与混合餐刺激C肽AUC、HbA1c和CGM数据进行关联分析。

主要发现

  • PedsQL和HFS评分个体间变异大,但个体内从诊断至48个月无实质性变化。
  • 基线评分高度预测12-48个月评分(p<0.001)。
  • 儿童PedsQL评分高于家长报告(p<0.01),家长HFS评分高于儿童(p<0.001)。
  • 儿童与家长评分之间强相关(p<0.001)。
  • 干预(ustekinumab或HCL)后这些评分未见显著改善。

关键数值与推荐

  • Meta分析显示HbA1c与PedsQL关联β(std)=-0.11(95% CI -0.20, -0.03),与HFS关联β(std)=0.11(95% CI 0.00, 0.21)。
  • CGM time in range与PedsQL关联β(std)=0.14(95% CI 0.03, 0.26),与HFS关联β(std)=-0.05(95% CI -0.16, 0.06)。
  • β细胞功能(AUC C肽)与HbA1c关联β(std)=-0.29(95% CI -0.39, -0.20),与CGM time in range关联β(std)=0.41(95% CI 0.30, 0.52)。
  • β细胞功能与PedsQL关联β(std)=0.11(95% CI -0.03, 0.25),与HFS关联β(std)=-0.05(95% CI -0.17, 0.07),均未达统计学显著性。

临床怎么用

  • 在新诊断1型糖尿病青少年中,PedsQL和HFS评分短期内相对稳定,可考虑作为基线评估工具。
  • PROMs与血糖管理指标关联适度,解读时应结合HbA1c和CGM数据。
  • PROMs对β细胞功能变化的敏感性有限,不宜单独作为β细胞保护试验的主要结局。

局限性

  • 研究仅纳入两项临床试验的10-18岁参与者,结论外推至其他年龄或人群需谨慎。
  • PROMs与β细胞功能的关联未达统计学显著性,可能受样本量限制。
  • 当前PROMs可能未充分适配使用现代糖尿病技术和接受疾病修饰治疗的年轻人。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Clinical trials of interventions to preserve beta cell function in new-onset type 1 diabetes frequently employ participant-reported outcome measures (PROMs). However, the expected changes in PROMs scores immediately following diagnosis and their association with residual beta cell function, metabolic markers and continuous glucose monitoring (CGM) are unclear. METHODS: Repeated PROMs including Paediatric Quality of Life Inventory diabetes module (PedsQL) and hypoglycaemia fear survey (HFS) were recorded from participants aged 10-18 years with newly diagnosed type 1 diabetes and their parents in two clinical trials: CLOuD (N=97, hybrid closed loop [HCL] vs multiple daily injections [MDI]) and USTEKID (N=72, ustekinumab immunotherapy vs placebo). Scores were compared with serial mixed meal-stimulated C-peptide levels (AUC C-peptide), HbA1c and CGM data. RESULTS: PedsQL and HFS scores for children/adolescents and their parents showed wide variation between individuals but did not change substantially within individuals over the first 48 months from diagnosis. Baseline scores were highly predictive of scores at 12-48 months (p<0.001). PedsQL scores were higher (better) in those reported by children/adolescents than by their parents (p<0.01). In contrast, HFS scores were higher in parents than children (p<0.001), indicating more fear. Strong correlations were observed between child and parent scores (p<0.001). No significant improvement in these scores was detected following intervention (ustekinumab or HCL). Meta-analysis revealed modest but statistically significant associations between HbA1c and PedsQL (β(std)=-0.11; 95% CI -0.20, -0.03) and HFS (β(std)=0.11; 95% CI 0.00, 0.21), and between CGM time in range and PedsQL (β(std)=0.14; 95% CI 0.03, 0.26) but not HFS (β(std)=-0.05; 95% CI -0.16, 0.06). Beta cell function (AUC C-peptide) was strongly associated with HbA1c (β(std)=-0.29; 95% CI -0.39, -0.20) and CGM time in range (β(std)=0.41; 95% CI 0.30, 0.52). Higher beta cell function showed a trend towards better PedsQL (β(std)=0.11; 95% CI -0.03, 0.25) and lower HFS (β(std)=-0.05; 95% CI -0.17, 0.07) but this did not reach statistical significance. CONCLUSIONS/INTERPRETATION: PedsQL and HFS scores changed little during the first 48 months after diagnosis of type 1 diabetes. These scores showed modest but statistically significant associations with measures of glucose management (HbA1c and CGM time in range), whereas the relationships with residual beta cell function (C-peptide) were weaker and did not reach significance. The modest size of these effects suggests current PROMs capture only limited aspects of the clinical benefit associated with beta cell preservation. Future research should incorporate psychometric instruments that are specifically adapted for young people using modern diabetes technologies and undergoing disease-modifying therapy, to ensure outcomes are meaningfully represented in early-stage type 1 diabetes trials.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Taylor PN, Cheung WY, Lagorio Price J, et al. Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes. Diabetologia. 2026. PMID: 42467087. doi:10.1007/s00125-026-06798-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。